Additional file 1: of Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients

Additional file 1: of Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury

Hamzah Abu-Sbeih (5791622)
Tenglong Tang (6309524)
Yang Lu (59885)
Selvi Thirumurthi (6309527)
Mehmet Altan (4337674)
Amir Jazaeri (6309530)
Ramona Dadu (5506082)
Emmanuel Coronel (6309533)
Yinghong Wang (174927)

February 2019

Table S1. Patient clinical characteristics by type of immune checkpoint inhibitor therapy. Table S2....

Additional file 1: of IgG4:IgG RNA ratio differentiates active disease from remission in granulomatosis with polyangiitis: a new disease activity marker? A cross-sectional and longitudinal study

A. Al-Soudi (6286022)
M. Doorenspleet (6286025)
R. Esveldt (6286028)
L. Burgemeister (6286031)
A. Hak (6286034)
B. Born (6286037)
S. Tas (6286040)
R. Vollenhoven (6286043)
P. Klarenbeek (6286046)
N. Vries (6286049)

February 2019

Supplementary methods. Table S1. BVAS division per active (a) and low disease activity (LDA) subject...

Additional file 1: Table S1. of Guidelines for treatment of immune-mediated cerebellar ataxias

Hiroshi Mitoma (3478301)
Marios Hadjivassiliou (251895)
JĂŠrĂ´me Honnorat (3478310)

November 2015

Efficacy of IVIg as induction therapy on gluten ataxia. Summary of four studies. (DOC 35 kb

Additional file 3: of Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients

Liwen Wang (276995)
Panpan Zhang (534098)
Mu Wang (235245)
Ruie Feng (305901)
Yamin Lai (5086049)
Linyi Peng (4966969)
Yunyun Fei (4966966)
Xuan Zhang (56049)
Yan Zhao (58882)
Xiaofeng Zeng (309980)
Fengchun Zhang (309978)
Wen Zhang (7555)

April 2018

Clinical features, treatments and outcomes of the patients with persistently active disease. (DOCX 7...

Additional file 4: of Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients

Liwen Wang (276995)
Panpan Zhang (534098)
Mu Wang (235245)
Ruie Feng (305901)
Yamin Lai (5086049)
Linyi Peng (4966969)
Yunyun Fei (4966966)
Xuan Zhang (56049)
Yan Zhao (58882)
Xiaofeng Zeng (309980)
Fengchun Zhang (309978)
Wen Zhang (7555)

April 2018

Clinical features, treatments and outcomes of the patients who relapsed during GC tapering. (DOCX 13...

Additional file 3: of Treatment of immunoglobulin G4-related sialadenitis: outcomes of glucocorticoid therapy combined with steroid-sparing agents

Xia Hong (1360752)
Yan-Yan Zhang (468715)
Wei Li (7081)
Yan-Ying Liu (4808616)
Zhen Wang (72451)
Yan Chen (4308)
Yan Gao (93649)
Zhi-Peng Sun (4808631)
Xin Peng (720270)
Jia-Zeng Su (4808613)
Zhi-Gang Cai (4808628)
Lei Zhang (38117)
Jing He (58446)
Li-Min Ren (4808625)
Hong-Yu Yang (4808622)
Zhan-Guo Li (309607)
Guang-Yan Yu (4808619)

January 2018

Supplementary figure for relationship between the short-term IgG4 levels after treatment and the bas...

Additional file 1: of Association of serum levels of fibrosis-related biomarkers with disease activity in patients with IgG4-related disease

Shin-ya Kawashiri (4003199)
Tomoki Origuchi (739149)
Masataka Umeda (1543771)
Ayako Nishino (4003187)
Toshimasa Shimizu (4003184)
Shoichi Fukui (4003181)
Tomohiro Koga (398369)
Naoki Iwamoto (4003208)
Kunihiro Ichinose (4003172)
Mami Tamai (4003175)
Hideki Nakamura (1543762)
Takahiro Maeda (396195)
Mitsuhiro Kawano (739143)
Motohisa Yamamoto (739148)
Yasumori Izumi (398365)
Atsushi Kawakami (398370)

December 2018

Table S1. Association between growth differentiation factor 15 (GDF-15) and organ involvements. Tabl...

Additional file 4: of Treatment of immunoglobulin G4-related sialadenitis: outcomes of glucocorticoid therapy combined with steroid-sparing agents

Xia Hong (1360752)
Yan-Yan Zhang (468715)
Wei Li (7081)
Yan-Ying Liu (4808616)
Zhen Wang (72451)
Yan Chen (4308)
Yan Gao (93649)
Zhi-Peng Sun (4808631)
Xin Peng (720270)
Jia-Zeng Su (4808613)
Zhi-Gang Cai (4808628)
Lei Zhang (38117)
Jing He (58446)
Li-Min Ren (4808625)
Hong-Yu Yang (4808622)
Zhan-Guo Li (309607)
Guang-Yan Yu (4808619)

January 2018

Supplementary tables for comparing the baseline features between different groups. (PDF 298 kb

Additional file 6: of Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports

Meng Tan (4246657)
Ravi Iyengar (120522)
Kara Mizokami-Stout (6253466)
Sarah Yentz (6253469)
Mark MacEachern (6253472)
Li Shen (110858)
Bruce Redman (6004508)
Roma Gianchandani (3517196)

January 2019

Appendix 6. Cases of Immune Checkpoint Inhibitor-Induced Endocrinopathies â Primary Adrenal Insuff...

Additional file 6: Table S4. of Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD

Fernando Leitao Filho (4855489)
Seung Ra (4055062)
Andre Mattman (4855486)
Robert Schellenberg (429772)
Gerard Criner (2993709)
Prescott Woodruff (4055044)
Stephen Lazarus (4055056)
Richard Albert (4055059)
John Connett (4055053)
Meilan Han (4055050)
Fernando Martinez (16458)
Janice Leung (3586403)
S. Paul Man (4855483)
Shawn Aaron (390256)
Robert Reed (4055047)
Don Sin (128552)

February 2018

Interactions between IgG subclass levels and inhaled steroid use at enrollment and use of systemic s...

Additional file 4: of IgG4:IgG RNA ratio differentiates active disease from remission in granulomatosis with polyangiitis: a new disease activity marker? A cross-sectional and longitudinal study

A. Al-Soudi (6286022)
M. Doorenspleet (6286025)
R. Esveldt (6286028)
L. Burgemeister (6286031)
A. Hak (6286034)
B. Born (6286037)
S. Tas (6286040)
R. Vollenhoven (6286043)
P. Klarenbeek (6286046)
N. Vries (6286049)

February 2019

Figure S3. Serum IgG4 vs qPCR test. Scatter dot plot portraying the correlation between serum IgG4 (...

Additional file 4: of Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports

Meng Tan (4246657)
Ravi Iyengar (120522)
Kara Mizokami-Stout (6253466)
Sarah Yentz (6253469)
Mark MacEachern (6253472)
Li Shen (110858)
Bruce Redman (6004508)
Roma Gianchandani (3517196)

January 2019

Appendix 4. Cases of Immune Checkpoint Inhibitors-Induced Endocrinopathies â Thyroid Disorders: (a...

Additional file 1: of Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet’s disease: a large-scale, long-term postmarketing surveillance in Japan

Shigeaki Ohno (3142857)
Itsuro Umebayashi (6177362)
Miyuki Matsukawa (4777236)
Takashi Goto (6177368)
Toshiro Yano (4411327)

January 2019

Figure S1. Re-infusion of IFX in patients with BD who developed IRs. Table S1. Independent factors a...

Additional file 1: of Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

Anne Bertrand (105293)
Marie Kostine (3571190)
Thomas Barnetche (91662)
Marie-Elise Truchetet (3585974)
Thierry Schaeverbeke (373935)

September 2015

Figures S5 to S7 Global immune-related adverse events (irAEs) with ipilimumab all dosage, 3 mg/kg, a...

Additional file 3: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies

Ling Li (38566)
Sheyu Li (147549)
Jiali Liu (327739)
Ke Deng (278265)
Jason Busse (3447368)
Per Vandvik (3542996)
Evelyn Wong (3542999)
Zahra Sohani (516750)
Malgorzata Bala (3542993)
Lorena Rios (120554)
German Malaga (354362)
Shanil Ebrahim (117426)
Jiantong Shen (448063)
Longhao Zhang (753873)
Pujing Zhao (753874)
Qunfei Chen (3543002)
Yingqiang Wang (505587)
Gordon Guyatt (56595)
Xin Sun (127355)

May 2016

Subgroup analysis of heart failure risk by type of control based on raw data of randomized controlle...

Additional file 1: of Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury

Hamzah Abu-Sbeih (5791622)
Tenglong Tang (6309524)
Yang Lu (59885)
Selvi Thirumurthi (6309527)
Mehmet Altan (4337674)
Amir Jazaeri (6309530)
Ramona Dadu (5506082)
Emmanuel Coronel (6309533)
Yinghong Wang (174927)

February 2019

Table S1. Patient clinical characteristics by type of immune checkpoint inhibitor therapy. Table S2....

Additional file 1: of IgG4:IgG RNA ratio differentiates active disease from remission in granulomatosis with polyangiitis: a new disease activity marker? A cross-sectional and longitudinal study

A. Al-Soudi (6286022)
M. Doorenspleet (6286025)
R. Esveldt (6286028)
L. Burgemeister (6286031)
A. Hak (6286034)
B. Born (6286037)
S. Tas (6286040)
R. Vollenhoven (6286043)
P. Klarenbeek (6286046)
N. Vries (6286049)

February 2019

Supplementary methods. Table S1. BVAS division per active (a) and low disease activity (LDA) subject...

Additional file 1: Table S1. of Guidelines for treatment of immune-mediated cerebellar ataxias

Hiroshi Mitoma (3478301)
Marios Hadjivassiliou (251895)
JĂŠrĂ´me Honnorat (3478310)

November 2015

Efficacy of IVIg as induction therapy on gluten ataxia. Summary of four studies. (DOC 35 kb

Additional file 3: of Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients

Liwen Wang (276995)
Panpan Zhang (534098)
Mu Wang (235245)
Ruie Feng (305901)
Yamin Lai (5086049)
Linyi Peng (4966969)
Yunyun Fei (4966966)
Xuan Zhang (56049)
Yan Zhao (58882)
Xiaofeng Zeng (309980)
Fengchun Zhang (309978)
Wen Zhang (7555)

April 2018

Clinical features, treatments and outcomes of the patients with persistently active disease. (DOCX 7...

Additional file 4: of Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients

Liwen Wang (276995)
Panpan Zhang (534098)
Mu Wang (235245)
Ruie Feng (305901)
Yamin Lai (5086049)
Linyi Peng (4966969)
Yunyun Fei (4966966)
Xuan Zhang (56049)
Yan Zhao (58882)
Xiaofeng Zeng (309980)
Fengchun Zhang (309978)
Wen Zhang (7555)

April 2018

Clinical features, treatments and outcomes of the patients who relapsed during GC tapering. (DOCX 13...

Additional file 3: of Treatment of immunoglobulin G4-related sialadenitis: outcomes of glucocorticoid therapy combined with steroid-sparing agents

Xia Hong (1360752)
Yan-Yan Zhang (468715)
Wei Li (7081)
Yan-Ying Liu (4808616)
Zhen Wang (72451)
Yan Chen (4308)
Yan Gao (93649)
Zhi-Peng Sun (4808631)
Xin Peng (720270)
Jia-Zeng Su (4808613)
Zhi-Gang Cai (4808628)
Lei Zhang (38117)
Jing He (58446)
Li-Min Ren (4808625)
Hong-Yu Yang (4808622)
Zhan-Guo Li (309607)
Guang-Yan Yu (4808619)

January 2018

Supplementary figure for relationship between the short-term IgG4 levels after treatment and the bas...

Additional file 1: of Association of serum levels of fibrosis-related biomarkers with disease activity in patients with IgG4-related disease

Shin-ya Kawashiri (4003199)
Tomoki Origuchi (739149)
Masataka Umeda (1543771)
Ayako Nishino (4003187)
Toshimasa Shimizu (4003184)
Shoichi Fukui (4003181)
Tomohiro Koga (398369)
Naoki Iwamoto (4003208)
Kunihiro Ichinose (4003172)
Mami Tamai (4003175)
Hideki Nakamura (1543762)
Takahiro Maeda (396195)
Mitsuhiro Kawano (739143)
Motohisa Yamamoto (739148)
Yasumori Izumi (398365)
Atsushi Kawakami (398370)

December 2018

Table S1. Association between growth differentiation factor 15 (GDF-15) and organ involvements. Tabl...

Additional file 4: of Treatment of immunoglobulin G4-related sialadenitis: outcomes of glucocorticoid therapy combined with steroid-sparing agents

Xia Hong (1360752)
Yan-Yan Zhang (468715)
Wei Li (7081)
Yan-Ying Liu (4808616)
Zhen Wang (72451)
Yan Chen (4308)
Yan Gao (93649)
Zhi-Peng Sun (4808631)
Xin Peng (720270)
Jia-Zeng Su (4808613)
Zhi-Gang Cai (4808628)
Lei Zhang (38117)
Jing He (58446)
Li-Min Ren (4808625)
Hong-Yu Yang (4808622)
Zhan-Guo Li (309607)
Guang-Yan Yu (4808619)

January 2018

Supplementary tables for comparing the baseline features between different groups. (PDF 298 kb

Additional file 6: of Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports

Meng Tan (4246657)
Ravi Iyengar (120522)
Kara Mizokami-Stout (6253466)
Sarah Yentz (6253469)
Mark MacEachern (6253472)
Li Shen (110858)
Bruce Redman (6004508)
Roma Gianchandani (3517196)

January 2019

Appendix 6. Cases of Immune Checkpoint Inhibitor-Induced Endocrinopathies â Primary Adrenal Insuff...

Additional file 6: Table S4. of Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD

Fernando Leitao Filho (4855489)
Seung Ra (4055062)
Andre Mattman (4855486)
Robert Schellenberg (429772)
Gerard Criner (2993709)
Prescott Woodruff (4055044)
Stephen Lazarus (4055056)
Richard Albert (4055059)
John Connett (4055053)
Meilan Han (4055050)
Fernando Martinez (16458)
Janice Leung (3586403)
S. Paul Man (4855483)
Shawn Aaron (390256)
Robert Reed (4055047)
Don Sin (128552)

February 2018

Interactions between IgG subclass levels and inhaled steroid use at enrollment and use of systemic s...

Additional file 4: of IgG4:IgG RNA ratio differentiates active disease from remission in granulomatosis with polyangiitis: a new disease activity marker? A cross-sectional and longitudinal study

A. Al-Soudi (6286022)
M. Doorenspleet (6286025)
R. Esveldt (6286028)
L. Burgemeister (6286031)
A. Hak (6286034)
B. Born (6286037)
S. Tas (6286040)
R. Vollenhoven (6286043)
P. Klarenbeek (6286046)
N. Vries (6286049)

February 2019

Figure S3. Serum IgG4 vs qPCR test. Scatter dot plot portraying the correlation between serum IgG4 (...

Additional file 4: of Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports

Meng Tan (4246657)
Ravi Iyengar (120522)
Kara Mizokami-Stout (6253466)
Sarah Yentz (6253469)
Mark MacEachern (6253472)
Li Shen (110858)
Bruce Redman (6004508)
Roma Gianchandani (3517196)

January 2019

Appendix 4. Cases of Immune Checkpoint Inhibitors-Induced Endocrinopathies â Thyroid Disorders: (a...

Additional file 1: of Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet’s disease: a large-scale, long-term postmarketing surveillance in Japan

Shigeaki Ohno (3142857)
Itsuro Umebayashi (6177362)
Miyuki Matsukawa (4777236)
Takashi Goto (6177368)
Toshiro Yano (4411327)

January 2019

Figure S1. Re-infusion of IFX in patients with BD who developed IRs. Table S1. Independent factors a...

Additional file 1: of Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

Anne Bertrand (105293)
Marie Kostine (3571190)
Thomas Barnetche (91662)
Marie-Elise Truchetet (3585974)
Thierry Schaeverbeke (373935)

September 2015

Figures S5 to S7 Global immune-related adverse events (irAEs) with ipilimumab all dosage, 3 mg/kg, a...

Additional file 3: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies

Ling Li (38566)
Sheyu Li (147549)
Jiali Liu (327739)
Ke Deng (278265)
Jason Busse (3447368)
Per Vandvik (3542996)
Evelyn Wong (3542999)
Zahra Sohani (516750)
Malgorzata Bala (3542993)
Lorena Rios (120554)
German Malaga (354362)
Shanil Ebrahim (117426)
Jiantong Shen (448063)
Longhao Zhang (753873)
Pujing Zhao (753874)
Qunfei Chen (3543002)
Yingqiang Wang (505587)
Gordon Guyatt (56595)
Xin Sun (127355)

May 2016

Subgroup analysis of heart failure risk by type of control based on raw data of randomized controlle...

Additional file 1: of Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury

Hamzah Abu-Sbeih (5791622)
Tenglong Tang (6309524)
Yang Lu (59885)
Selvi Thirumurthi (6309527)
Mehmet Altan (4337674)
Amir Jazaeri (6309530)
Ramona Dadu (5506082)
Emmanuel Coronel (6309533)
Yinghong Wang (174927)

February 2019

Table S1. Patient clinical characteristics by type of immune checkpoint inhibitor therapy. Table S2....

Additional file 1: of IgG4:IgG RNA ratio differentiates active disease from remission in granulomatosis with polyangiitis: a new disease activity marker? A cross-sectional and longitudinal study

A. Al-Soudi (6286022)
M. Doorenspleet (6286025)
R. Esveldt (6286028)
L. Burgemeister (6286031)
A. Hak (6286034)
B. Born (6286037)
S. Tas (6286040)
R. Vollenhoven (6286043)
P. Klarenbeek (6286046)
N. Vries (6286049)

February 2019

Supplementary methods. Table S1. BVAS division per active (a) and low disease activity (LDA) subject...

Additional file 1: Table S1. of Guidelines for treatment of immune-mediated cerebellar ataxias

Hiroshi Mitoma (3478301)
Marios Hadjivassiliou (251895)
JĂŠrĂ´me Honnorat (3478310)

November 2015

Efficacy of IVIg as induction therapy on gluten ataxia. Summary of four studies. (DOC 35 kb

Additional file 1: of Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients

Abstract

Extracted data

Additional file 1: of Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients

Abstract

Extracted data

Related items

Related items